- Forums
- ASX - By Stock
- AVR
- Ann: Admedus Releases Results of HSV-2 Phase IIa Study
Ann: Admedus Releases Results of HSV-2 Phase IIa Study, page-330
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$18.23 |
Change
-0.120(0.65%) |
Mkt cap ! $341.1M |
Open | High | Low | Value | Volume |
$18.36 | $18.47 | $17.55 | $151.6K | 8.46K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 4 | $17.91 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$18.23 | 49 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 4 | 17.910 |
1 | 200 | 17.900 |
1 | 103 | 17.850 |
1 | 1585 | 17.750 |
1 | 150 | 17.700 |
Price($) | Vol. | No. |
---|---|---|
18.230 | 49 | 5 |
18.270 | 573 | 2 |
18.300 | 37 | 1 |
18.310 | 38 | 1 |
18.390 | 25 | 1 |
Last trade - 14.21pm 03/07/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO & MD
Anthony Noble
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online